Tempest Therapeutics, Inc. - Common Stock (TPST)

San Francisco, CA – November 19, 2025 – Tempest Therapeutics, Inc. (NASDAQ: TPST) saw its stock price plummet by a staggering 48.92% today, wiping out nearly half of its market value in a single trading session. The dramatic decline was a direct response to the company's announcement of an all-stock acquisition

The transaction is expected to close in early 2026, provided it receives all required approvals.

Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients with unresectable hepatocellular carcinoma.

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin in Q1 2025.